Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Neumora Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
Latest Hotspot
8 min read
Neumora Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Neumora Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
NCT07606365 Geographic Atrophy Geographic Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07606365 Geographic Atrophy Geographic Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07606365, evaluating Geographic Atrophy in Geographic Atrophy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Harmony Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
Latest Hotspot
8 min read
Harmony Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Harmony Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
NCT07303296 Lenadogene nolparvovec Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07303296 Lenadogene nolparvovec Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07303296, evaluating Lenadogene nolparvovec in Leber Hereditary Optic Neuropathy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
Axsome Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
Latest Hotspot
8 min read
Axsome Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Axsome Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Read →
NCT07568236 Fezolinetant Menopausal Vasomotor Symptoms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07568236 Fezolinetant Menopausal Vasomotor Symptoms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07568236, evaluating Fezolinetant in Menopausal Vasomotor Symptoms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07703280 Osteoarthritis Disease Modification Osteoarthritis Disease Modification Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07703280 Osteoarthritis Disease Modification Osteoarthritis Disease Modification Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07703280, evaluating Osteoarthritis Disease Modification in Osteoarthritis Disease Modification: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07695207 Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular De… Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07695207 Neovascular Age-Related Macular Degeneration Neovascular Age-Related Macular De… Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07695207, evaluating Neovascular Age-Related Macular Degeneration in Neovascular Age-Related Macular Degeneration: trial design, endpoint strategy, sponsor context, benchmark readouts and developme…
Read →
NCT07406854 Esonadogene Imvoparvovec Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07406854 Esonadogene Imvoparvovec Leber Hereditary Optic Neuropathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07406854, evaluating Esonadogene Imvoparvovec in Leber Hereditary Optic Neuropathy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07682402 Taurine Long COVID Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07682402 Taurine Long COVID Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07682402, evaluating Taurine in Long COVID: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07696520 Bepirovirsen Chronic Hepatitis B Functional Cure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07696520 Bepirovirsen Chronic Hepatitis B Functional Cure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07696520, evaluating Bepirovirsen in Chronic Hepatitis B Functional Cure: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →
NCT07486024 Bedaquiline Fumarate Drug-Resistant Tuberculosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486024 Bedaquiline Fumarate Drug-Resistant Tuberculosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07486024, evaluating Bedaquiline Fumarate in Drug-Resistant Tuberculosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Read →